Dr. Wander: CDK4/6 Inhibitor Efficacy and Safety Results in High-Risk HR+, HER2- EBC
Join Dr. Wander as he reviews safety and efficacy data for FDA-approved CDK4/6 inhibitors in high-risk HR+, HER2- EBC. This video equips HCPs with insights to enhance understanding and improve clinical decision-making for patients
Date of Last Review: December 11, 2024
Document Number: VV-MED-160301
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice